Skip to main content

Table 1 Baseline characteristics

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Sex (Male/Female)

44/42

Age (years)

59.8 ± 12.8

Duration of diabetes (years)

15.8 ± 9.5

HbA1c (%)

8.5 ± 1.5

Body mass index (kg/m2)

27.3 ± 5.4

Waist circumference (cm)

100.2 ± 11.3

LDL-C (mg/dL)

108.9 ± 33.4

HDL-C (mg/dL)

47.2 ± 13.8

Triglycerides (mg/dL)

136.9 ± 76.3

Hypertension (%)

86

Dyslipidemia (%)

90

Medication for Diabetes

 

BG (%)

49

SU (%)

43

αGI (%)

22

TZD (%)

13

DPP4i (%)

17

Glinide (%)

3

Insulin (%)

56

  1. Data are mean ± SD or number of subjects. LDL-C; low-density lipoprotein-cholesterol, HDL-C; high-density lipoprotein-cholesterol, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.